Dianthus Therapeutics, Inc. /DE/ APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Dianthus Therapeutics, Inc. /DE/ (DNTH) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $11.90 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-04
- Dianthus Therapeutics, Inc. /DE/ apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $11.90M, a 108.52% increase year-over-year.
- Dianthus Therapeutics, Inc. /DE/ apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $10.60M, a 99.47% increase year-over-year.
- Dianthus Therapeutics, Inc. /DE/ apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $5.79M, a 50.89% increase year-over-year.
- Dianthus Therapeutics, Inc. /DE/ apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $5.71M, a 84.01% increase year-over-year.
- Dianthus Therapeutics, Inc. /DE/ apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $22.79M, a 76.77% increase from fiscal 2024.
- Dianthus Therapeutics, Inc. /DE/ apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $12.89M, a 344.62% increase from fiscal 2023.
- Dianthus Therapeutics, Inc. /DE/ apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $2.90M, a 91.04% increase from fiscal 2022.
- Dianthus Therapeutics, Inc. /DE/ apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $1.52M.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $11.90M 10-Q · filed 2026-08-04 | $22.50M derived: sum of 2 quarters · filed 2026-08-04 | ||||
| 2026-03-31 | $10.60M 10-Q · filed 2026-08-04 | |||||
| 2025-12-31 | $22.79M 10-K · filed 2026-03-09 | |||||
| 2025-09-30 | $5.79M 10-Q · filed 2025-11-05 | $11.50M derived: sum of 2 quarters · filed 2026-08-04 | $16.82M derived: sum of 3 quarters · filed 2026-08-04 | |||
| 2025-06-30 | $5.71M 10-Q · filed 2026-08-04 | $11.02M derived: sum of 2 quarters · filed 2026-08-04 | ||||
| 2025-03-31 | $5.32M 10-Q · filed 2026-08-04 | |||||
| 2024-12-31 | $12.89M 10-K · filed 2026-03-09 | |||||
| 2024-09-30 | $3.84M 10-Q · filed 2025-11-05 | $6.94M derived: sum of 2 quarters · filed 2025-11-05 | $8.98M derived: sum of 3 quarters · filed 2025-11-05 | |||
| 2024-06-30 | $3.10M 10-Q · filed 2025-11-05 | $5.14M derived: sum of 2 quarters · filed 2025-11-05 | ||||
| 2024-03-31 | $2.04M 10-Q · filed 2025-11-05 | |||||
| 2023-12-31 | $2.90M 10-K · filed 2025-03-11 | |||||
| 2023-09-30 | $1.18M 10-Q · filed 2024-11-07 | $1.64M derived: sum of 2 quarters · filed 2024-11-07 | $2.17M derived: sum of 3 quarters · filed 2024-11-07 | -$1.56M derived: sum of 4 quarters · filed 2024-11-07 | ||
| 2023-06-30 | $462.00K 10-Q · filed 2024-11-07 | $416.00K 10-Q · filed 2023-08-03 | $922.00K 10-Q · filed 2023-08-03 | -$2.74M derived: sum of 3 quarters · filed 2024-11-07 | -$2.08M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-03-31 | $533.00K 10-Q · filed 2024-11-07 | $506.00K 10-Q · filed 2023-05-15 | -$3.21M derived: sum of 2 quarters · filed 2024-11-07 | -$2.54M derived: sum of 3 quarters · filed 2024-11-07 | -$2.27M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2022-12-31 | -$3.74M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$3.08M derived: sum of 2 quarters · filed 2024-03-21 | -$2.80M derived: sum of 3 quarters · filed 2024-03-21 | $1.52M 10-K · filed 2024-03-21 | $7.02M 10-K · filed 2023-03-23 | |
| 2022-09-30 | $661.00K 10-Q · filed 2023-11-09 | $1.51M 10-Q · filed 2022-11-03 | $940.00K derived: sum of 2 quarters · filed 2023-11-09 | $5.26M 10-Q · filed 2022-11-03 | -$7.06M derived: sum of 4 quarters · filed 2023-12-21 | |
| 2022-06-30 | $279.00K 10-Q · filed 2023-11-09 | $1.84M 10-Q · filed 2022-08-04 | $3.75M 10-Q · filed 2023-08-03 | -$7.72M derived: sum of 3 quarters · filed 2023-12-21 | -$3.92M derived: sum of 4 quarters · filed 2023-12-21 | |
| 2022-03-31 | $65.00K 10-Q · filed 2023-11-09 | $1.91M 10-Q · filed 2022-05-16 | -$8.00M derived: sum of 2 quarters · filed 2023-12-21 | -$4.20M derived: sum of 3 quarters · filed 2023-12-21 | -$2.06M derived: sum of 4 quarters · filed 2023-12-21 | |
| 2021-12-31 | -$8.06M derived: 8-K 12 month − 10-Q 9 month · filed 2023-12-21 | -$4.26M derived: sum of 2 quarters · filed 2023-12-21 | -$2.13M derived: sum of 3 quarters · filed 2023-12-21 | $63.00K 8-K · filed 2023-12-21 | $10.31M 10-K · filed 2022-03-08 | |
| 2021-09-30 | $3.80M 10-Q · filed 2022-11-03 | $5.93M derived: sum of 2 quarters · filed 2022-11-03 | $8.13M 10-Q · filed 2022-11-03 | $10.46M derived: sum of 4 quarters · filed 2022-11-03 | ||
| 2021-06-30 | $2.13M 10-Q · filed 2022-08-04 | $4.33M 10-Q · filed 2022-08-04 | $6.66M derived: sum of 3 quarters · filed 2022-08-04 | $9.02M derived: sum of 4 quarters · filed 2022-08-04 | ||
| 2021-03-31 | $2.19M 10-Q · filed 2022-05-16 | $4.52M derived: sum of 2 quarters · filed 2022-05-16 | $6.89M derived: sum of 3 quarters · filed 2022-05-16 | $9.39M derived: sum of 4 quarters · filed 2022-05-16 | ||
| 2020-12-31 | $2.33M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $4.70M derived: sum of 2 quarters · filed 2022-03-08 | $7.20M derived: sum of 3 quarters · filed 2022-03-08 | $9.94M 10-K · filed 2022-03-08 | ||
| 2020-09-30 | $2.37M 10-Q · filed 2021-11-04 | $4.87M derived: sum of 2 quarters · filed 2021-11-04 | $7.61M 10-Q · filed 2021-11-04 | $9.67M derived: sum of 4 quarters · filed 2021-11-04 | ||
| 2020-06-30 | $2.50M 10-Q · filed 2021-08-05 | $5.24M 10-Q · filed 2021-08-05 | $7.31M derived: sum of 3 quarters · filed 2021-08-05 | $10.07M derived: sum of 4 quarters · filed 2021-08-05 | ||
| 2020-03-31 | $2.74M 10-Q · filed 2021-05-06 | $4.80M derived: sum of 2 quarters · filed 2021-05-06 | $7.56M derived: sum of 3 quarters · filed 2021-05-06 | $10.16M derived: sum of 4 quarters · filed 2021-05-06 | ||
| 2019-12-31 | $2.06M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-03 | $4.82M derived: sum of 2 quarters · filed 2021-03-03 | $7.42M derived: sum of 3 quarters · filed 2021-03-03 | $10.00M 10-K · filed 2021-03-03 | ||
| 2019-09-30 | $2.76M 10-Q · filed 2020-11-05 | $5.36M derived: sum of 2 quarters · filed 2020-11-05 | $7.94M 10-Q · filed 2020-11-05 | $10.49M derived: sum of 4 quarters · filed 2020-11-05 | ||
| 2019-06-30 | $2.60M 10-Q · filed 2020-08-06 | $5.18M 10-Q · filed 2020-08-06 | $7.73M derived: sum of 3 quarters · filed 2020-08-06 | $11.40M derived: sum of 4 quarters · filed 2020-08-06 | ||
| 2019-03-31 | $2.58M 10-Q · filed 2020-05-07 | $5.13M derived: sum of 2 quarters · filed 2020-05-07 | $8.80M derived: sum of 3 quarters · filed 2020-05-07 | $11.86M derived: sum of 4 quarters · filed 2020-05-07 | ||
| 2018-12-31 | $2.55M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-03 | $6.23M derived: sum of 2 quarters · filed 2020-03-03 | $9.28M derived: sum of 3 quarters · filed 2020-03-03 | $10.70M 10-K · filed 2020-03-03 | ||
| 2018-09-30 | $3.68M 10-Q · filed 2019-11-13 | $6.73M derived: sum of 2 quarters · filed 2019-11-13 | $8.15M 10-Q · filed 2019-11-13 | |||
| 2018-06-30 | $3.05M 10-Q · filed 2019-08-08 | $4.48M derived: sum of 2 quarters · filed 2019-08-08 | ||||
| 2018-03-31 | $1.43M 10-Q · filed 2019-08-08 | |||||
| 2017-12-31 | $2.26M 10-K · filed 2020-03-03 | |||||
| 2016-12-31 | $662.00K 10-K · filed 2019-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |